Biotechnology
Compare Stocks
4 / 10Stock Comparison
GOVX vs SIGA vs NVAX vs AGEN
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Biotechnology
Biotechnology
GOVX vs SIGA vs NVAX vs AGEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Biotechnology | Biotechnology |
| Market Cap | $2M | $339M | $1.50B | $132M |
| Revenue (TTM) | $2M | $94M | $596M | $114M |
| Net Income (TTM) | $-21M | $-4.04T | $-88M | $115K |
| Gross Margin | 100.0% | 61.8% | 84.6% | 35.7% |
| Operating Margin | -8.7% | 27.7% | -11.2% | -17.7% |
| Forward P/E | — | 2.8x | 3.6x | 1.8x |
| Total Debt | $843.17B | $595K | $249M | $10M |
| Cash & Equiv. | $6M | $155M | $241M | $3M |
GOVX vs SIGA vs NVAX vs AGEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | 100 | 3.7 | -96.3% |
| SIGA Technologies, … (SIGA) | 100 | 68.9 | -31.1% |
| Novavax, Inc. (NVAX) | 100 | 8.5 | -91.5% |
| Agenus Inc. (AGEN) | 100 | 4.7 | -95.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GOVX vs SIGA vs NVAX vs AGEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GOVX is the clearest fit if your priority is momentum.
- +89.4% vs SIGA's +1.5%
SIGA is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 4 yrs, beta 1.15, yield 12.7%
- 7.6% 10Y total return vs NVAX's -90.4%
- Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
- Beta 1.15, yield 12.7%, current ratio 11.83x
NVAX is the clearest fit if your priority is growth exposure.
- Rev growth 64.7%, EPS growth 306.5%, 3Y rev CAGR -11.1%
- 64.7% revenue growth vs GOVX's -37.1%
AGEN carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (1.8x vs 3.6x)
- 0.1% margin vs SIGA's -43K%
- 0.1% ROA vs NVAX's -7.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 64.7% revenue growth vs GOVX's -37.1% | |
| Value | Lower P/E (1.8x vs 3.6x) | |
| Quality / Margins | 0.1% margin vs SIGA's -43K% | |
| Stability / Safety | Beta 1.15 vs AGEN's 2.72 | |
| Dividends | 12.7% yield; 4-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +89.4% vs SIGA's +1.5% | |
| Efficiency (ROA) | 0.1% ROA vs NVAX's -7.4% |
GOVX vs SIGA vs NVAX vs AGEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GOVX vs SIGA vs NVAX vs AGEN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SIGA leads in 2 of 6 categories
GOVX leads 0 • NVAX leads 0 • AGEN leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — GOVX and SIGA and AGEN each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVAX is the larger business by revenue, generating $596M annually — 239.6x GOVX's $2M. AGEN is the more profitable business, keeping 0.1% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, AGEN holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $94M | $596M | $114M |
| EBITDAEarnings before interest/tax | -$22M | $26M | -$47M | -$10M |
| Net IncomeAfter-tax profit | -$21M | -$4.04T | -$88M | $115,000 |
| Free Cash FlowCash after capex | -$21M | $33M | -$96M | -$159M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +61.8% | +84.6% | +35.7% |
| Operating MarginEBIT ÷ Revenue | -8.7% | +27.7% | -11.2% | -17.7% |
| Net MarginNet income ÷ Revenue | -8.6% | -43117.4% | -14.7% | +0.1% |
| FCF MarginFCF ÷ Revenue | -8.6% | +35.2% | -16.1% | -139.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -11.3% | -79.1% | +27.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +86.9% | — | -102.0% | +85.3% |
Valuation Metrics
Evenly matched — GOVX and AGEN each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 3.6x trailing earnings, NVAX trades at a 75% valuation discount to SIGA's 14.3x P/E. On an enterprise value basis, NVAX's 2.6x EV/EBITDA is more attractive than SIGA's 7.6x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $2M | $339M | $1.5B | $132M |
| Enterprise ValueMkt cap + debt − cash | $843.2B | $185M | $1.5B | $140M |
| Trailing P/EPrice ÷ TTM EPS | -0.08x | 14.33x | 3.63x | -1102.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 2.78x | — | 1.79x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.60x | 2.56x | — |
| Price / SalesMarket cap ÷ Revenue | 0.68x | 3.58x | 1.34x | 1.16x |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.70x | — | — |
| Price / FCFMarket cap ÷ FCF | — | 6.96x | — | — |
Profitability & Efficiency
SIGA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
GOVX delivers a -0.0% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-11 for SIGA. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to GOVX's 0.22x. On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs GOVX's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -0.0% | -10.7% | — | — |
| ROA (TTM)Return on assets | -0.0% | -7.4% | -7.4% | +0.1% |
| ROICReturn on invested capital | -0.0% | +33.7% | — | — |
| ROCEReturn on capital employed | -0.0% | +11.3% | +100.4% | — |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.22x | 0.00x | — | — |
| Net DebtTotal debt minus cash | $843.2B | -$154M | $8M | $7M |
| Cash & Equiv.Liquid assets | $6M | $155M | $241M | $3M |
| Total DebtShort + long-term debt | $843.2B | $595,169 | $249M | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | — | -5.10x | 1.11x |
Total Returns (Dividends Reinvested)
Evenly matched — GOVX and SIGA and NVAX each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SIGA five years ago would be worth $10,136 today (with dividends reinvested), compared to $197 for GOVX. Over the past 12 months, GOVX leads with a +89.4% total return vs SIGA's +1.5%. The 3-year compound annual growth rate (CAGR) favors NVAX at 7.4% vs AGEN's -51.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +750.2% | -15.0% | +29.5% | +16.1% |
| 1-Year ReturnPast 12 months | +89.4% | +1.5% | +55.1% | +27.1% |
| 3-Year ReturnCumulative with dividends | -82.4% | +22.2% | +23.9% | -88.2% |
| 5-Year ReturnCumulative with dividends | -98.0% | +1.4% | -94.8% | -93.9% |
| 10-Year ReturnCumulative with dividends | -96.0% | +764.0% | -90.4% | -94.3% |
| CAGR (3Y)Annualised 3-year return | -43.9% | +6.9% | +7.4% | -51.0% |
Risk & Volatility
Evenly matched — SIGA and NVAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
SIGA is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVAX currently trades 77.1% from its 52-week high vs GOVX's 40.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.23x | 1.15x | 2.11x | 2.72x |
| 52-Week HighHighest price in past year | $4.40 | $9.62 | $11.97 | $7.34 |
| 52-Week LowLowest price in past year | $0.12 | $4.29 | $5.80 | $2.71 |
| % of 52W HighCurrent price vs 52-week peak | +40.0% | +49.2% | +77.1% | +51.1% |
| RSI (14)Momentum oscillator 0–100 | 67.8 | 47.0 | 64.4 | 48.8 |
| Avg Volume (50D)Average daily shares traded | 217K | 688K | 4.4M | 814K |
Analyst Outlook
SIGA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SIGA as "Buy", NVAX as "Buy", AGEN as "Buy". Consensus price targets imply 95.5% upside for AGEN (target: $7) vs 95.0% for NVAX (target: $18). SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $18.00 | $7.33 |
| # AnalystsCovering analysts | — | 1 | 23 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | +12.7% | — | — |
| Dividend StreakConsecutive years of raises | — | 4 | 1 | 1 |
| Dividend / ShareAnnual DPS | — | $0.60 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.3% | +0.1% |
SIGA leads in 2 of 6 categories — strongest in Profitability & Efficiency and Analyst Outlook. 4 categories are tied.
GOVX vs SIGA vs NVAX vs AGEN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GOVX or SIGA or NVAX or AGEN a better buy right now?
For growth investors, Novavax, Inc.
(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -37. 1% for GeoVax Labs, Inc. (GOVX). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GOVX or SIGA or NVAX or AGEN?
On trailing P/E, Novavax, Inc.
(NVAX) is the cheapest at 3. 6x versus SIGA Technologies, Inc. at 14. 3x. On forward P/E, Agenus Inc. is actually cheaper at 1. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — GOVX or SIGA or NVAX or AGEN?
Over the past 5 years, SIGA Technologies, Inc.
(SIGA) delivered a total return of +1. 4%, compared to -98. 0% for GeoVax Labs, Inc. (GOVX). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus GOVX's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GOVX or SIGA or NVAX or AGEN?
By beta (market sensitivity over 5 years), SIGA Technologies, Inc.
(SIGA) is the lower-risk stock at 1. 15β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 137% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 22% for GeoVax Labs, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — GOVX or SIGA or NVAX or AGEN?
By revenue growth (latest reported year), Novavax, Inc.
(NVAX) is pulling ahead at 64. 7% versus -37. 1% for GeoVax Labs, Inc. (GOVX). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, GOVX leads at 212. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GOVX or SIGA or NVAX or AGEN?
Novavax, Inc.
(NVAX) is the more profitable company, earning 39. 2% net margin versus -862. 3% for GeoVax Labs, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -869. 3% for GOVX. At the gross margin level — before operating expenses — GOVX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GOVX or SIGA or NVAX or AGEN more undervalued right now?
On forward earnings alone, Agenus Inc.
(AGEN) trades at 1. 8x forward P/E versus 2. 8x for SIGA Technologies, Inc. — 1. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 95. 5% to $7. 33.
08Which pays a better dividend — GOVX or SIGA or NVAX or AGEN?
In this comparison, SIGA (12.
7% yield) pays a dividend. GOVX, NVAX, AGEN do not pay a meaningful dividend and should not be held primarily for income.
09Is GOVX or SIGA or NVAX or AGEN better for a retirement portfolio?
For long-horizon retirement investors, SIGA Technologies, Inc.
(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). GeoVax Labs, Inc. (GOVX) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, GOVX: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GOVX and SIGA and NVAX and AGEN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GOVX is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; NVAX is a small-cap high-growth stock; AGEN is a small-cap quality compounder stock. SIGA pays a dividend while GOVX, NVAX, AGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.